BACKGROUND Donepezil hydrochloride is a selective acetylcholinesterase inhibitor approved for the symptomatic treatment of mild to moderately severe Alzheimer disease (AD). Controlled clinical trials of up to 24 weeks have demonstrated that donepezil treatment (5 and 10 mg/d) significantly improves cognition and global function. OBJECTIVE To investigate the long-term benefits of donepezil tre...

OBJECTIVE To determine the efficacy of donepezil hydrochloride for the treatment of Alzheimer disease in patients drawn from clinical practice. DESIGN Two-center, randomized, placebo-controlled, double-masked crossover study. SETTING Memory disorders units at Massachusetts General and Brigham and Women's hospitals, Boston. PATIENTS Sixty individuals (30 men and 30 women; mean +/- SD age, ...

STUDY OBJECTIVE Examine the effects of donepezil on sleep and rapid eye movement (REM) sleep electroencephalogram (EEG) in patients with Alzheimer disease, using polysomnography, and the correlation between REM sleep EEG parameters and cognitive scores. DESIGN Randomized, double-blind, placebo-controlled design. SETTINGS Two sleep research centers, University Hospital. PARTICIPANTS Thirty...

The 5-HT6 receptor is a promising target for cognitive disorders, in particular for Alzheimer's disease (AD) and other CNS disorders. The high-affinity and selective 5-HT6 receptor antagonist idalopirdine (Lu AE58054) is currently in development for mild-moderate AD as adjunct therapy to acetylcholinesterase inhibitors (AChEIs). We studied the effects of idalopirdine alone and in combination wi...

GOAL Combinatorial therapy directed at both vascular and neurodegenerative aspects of dementia may offer a promising strategy for treatment of dementia, which often has a multifactorial basis in the elderly. We investigated whether the phosphodiesterase III inhibitor cilostazol, which is often used in the prevention of stroke and peripheral artery disease, may delay cognitive decline in the eld...

OBJECTIVE To provide pilot data for the safety and efficacy of EGb 761 in the oldest-old patients (aged 80 or older). MATERIALS AND METHODS In a retrospective analysis, we compared treatment outcomes with EGb 761 or donepezil over 12 months in 189 patients aged 80 years or older suffering from Alzheimer's disease (AD). RESULTS Over 12 months, there was no significant difference in cognitive...

OBJECTIVE To compare levels of persistency with 2 cholinesterase (ChE) inhibitors--rivastigmine and donepezil--for the treatment of Alzheimer's disease (AD) through the use of administrative claims data. METHODS This retrospective cohort study identified treatment-naive, community-based AD patients having an initial prescription (index event) for rivastigmine or donepezil between June and Dec...

objective(s): alzheimer’s disease (ad) as progressive cognitive decline and the most common form of dementia is due to degeneration of the cholinergic neurons in the brain. therefore, administration of the acetylcholinesterase (ache) inhibitors such as donepezil is the first choice for treatment of the ad. in the present study, we focused on the synthesis and anti-cholinesterase evaluation of n...

Previous studies reported some relationships between donepezil treatment and hippocampus in Alzheimer's disease (AD). However, due to methodological limitations, their close relationships remain unclear. The aim of this study is to predict treatment response to donepezil by utilizing the automated segmentation of hippocampal subfields volumes (ASHS) in AD. Sixty four AD patients were prescribed...

BACKGROUND Recent data indicate that the rs1080985 single nucleotide polymorphism of the cytochrome P450 (CYP) 2D6 gene may affect the response to treatment with donepezil in patients with Alzheimer's disease. There is also evidence that the common apolipoprotein E (APOE) polymorphism may affect the response to treatment with donepezil in Alzheimer's disease. We investigated the association bet...